The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
Open accessAbstract
BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic colorectal cancer is unknown. METHODS: In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks. Patients receiving chemotherapy could cross over to pembrolizumab therapy after disease progression. The two primary end points were progression-free survival and overall survival. RESULTS: At the second interim analysis, after a median follow-up (from randomization to data cutoff) of 32.4 months (range, 24.0 to 48.3), pembrolizumab was superior to chemotherapy with respect to progression-free survival (median, 16.5 vs. 8.2 months; hazard ratio, 0.60; 95% confidence interval [CI], 0.45 to 0.80; P = 0.0002). The estimated restricted mean survival after 24 months of follow-up was 13.7 months (range, 12.0 to 15.4) as compared with 10.8 months (range, 9.4 to 12.2). As of the data cutoff date, 56 patients in the pembrolizumab group and 69 in the chemotherapy group had died. Data on overall survival were still evolving (66% of required events had occurred) and remain blinded until the final analysis. An overall response (complete or partial response), as evaluated with Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was observed in 43.8% of the patients in the pembrolizumab group and 33.1% in the chemotherapy group. Among patients with an overall response, 83% in the pembrolizumab group, as compared with 35% of patients in the chemotherapy group, had ongoing responses at 24 months. Treatment-related adverse events of grade 3 or higher occurred in 22% of the patients in the pembrolizumab group, as compared with 66% (including one patient who died) in the chemotherapy group. CONCLUSIONS: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among patients with a response, treatment responses were durable at 24 months in 83% of patients treated with pembrolizumab versus 33.1% among patients who received standard chemotherapy.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [76]
In the citing paper
“Pembrolizumab was associated with improved progression-free survival (median 16.5 months versus 8.2 months, HR 0.60, p < 0.001) and mean overall survival (13.7 months versus 10.8 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [76]
In the citing paper
“In 2020, the phase III Keynote-177 trial confirmed the superiority of pembrolizumab compared with chemotherapy with or without anti-VEGF/anti-EGFR in the first-line treatment of metastatic dMMR/MSI-H CRC.101”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [101]
In the citing paper
“careful analysis of clinical trials shows that a relevant proportion of patients with metastatic dMMR/MSI-H CRC still do not respond to immune checkpoint blockade101 107 with tumour progression within the first 6 months (up to 50% and up to 25% in single and double agent ICB therapy, respectively)”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [101]
In the citing paper
“However, despite the high rate of durable responses, a fraction of them will develop immune resistance that can outweigh prolonged survival outcomes (approximately 15–29%) [12,15,16].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Marabelle, A., Le, D. T., Ascierto, P. A., Giacomo, A. M. D., Jesus‐Acosta, A. D., Delord, J., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,122
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationIonov, Y., Peinado, M. A., Malkhosyan, S. R., Shibata, D. K., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,691
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Cited by
Sorted by citations
Items 501–600 of 1,003
Immunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 31
Self-citationExploiting unique features of the gut-brain interface to combat gastrointestinal cancer
Schledwitz, A., Xie, G., & Raufman, J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143776 · Cited by 31
Yang, K., Han, L., Wu, S., Qu, X., Li, Q., Zhao, C., Zhou, J., Jin, X. S., Wang, Y., Dong, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03083-3 · Cited by 30
Olivares-Hernández, A., del Barco, E., Pérez, C. P., Miramontes‐González, J. P., Figuero-Pérez, L., Gómez, T. M., Cornejo, R. A. E., Hernández, L. B., González‐Sarmiento, R., Cruz, J. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020360 · Cited by 30
Gorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 30
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras, E., Zerdes, I., Tsiknakis, N., Manikis, G. C., Mezheyeuski, A., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2022) · Cancers · doi:10.3390/cancers14081999 · Cited by 30
Jung, M., Lee, J. A., Yoo, S., Bae, J. M., Kang, G. H., & Kim, J. H. (2022) · Modern Pathology · doi:10.1038/s41379-022-01137-0 · Cited by 30
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Xu, Y., Nowsheen, S., & Deng, M. (2023) · Cancers · doi:10.3390/cancers15051619 · Cited by 31
Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Yoon, W.-H., DeFazio, A., & Kasherman, L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.13 · Cited by 31
Sanjaya, P., Maljanen, K., Katainen, R., Waszak, S. M., Ambrose, J. C., Arumugam, P., Bevers, R. P. J., Bleda, M., Boardman-Pretty, F., Boustred, C. R., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01204-4 · Cited by 31
Yang, J., Du, Y., Yao, Y., Liao, Y., Wang, B., Yu, X., Yuan, K., Zhang, Y., He, F., & Yang, P. (2024) · Advanced Science · doi:10.1002/advs.202307130 · Cited by 30
Self-citationChung, S., Chang, Y., Hsu, D. S., Hung, Y.-C., Lu, M.-L., Hung, Y., Chiang, N., Yeh, C., Hsiao, M., Soong, J., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100856 · Cited by 29
Gene-based burden tests of rare germline variants identify six cancer susceptibility genes
Ivarsdottir, E. V., Guðmundsson, J., Tragante, V., Sveinbjörnsson, G., Kristmundsdóttir, S., Stacey, S., Halldorsson, G. H., Magnusson, M. I., Oddsson, Á., Walters, G. B., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01966-6 · Cited by 29
Ikoma, T., Shimokawa, M., Kotaka, M., Matsumoto, T., Nagai, H., Boku, S., Shibata, N., Yasui, H., & Satake, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08271-z · Cited by 29
Marino, F. Z., Amato, M., Ronchi, A., Panarese, I., Ferraraccio, F., Vita, F. D., Tirino, G., Martinelli, E., Troiani, T., Facchini, G., et al. (2022) · Cancers · doi:10.3390/cancers14092204 · Cited by 29
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy
Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 31
Shah, N. J., Cook, M. R., Wu, T., Ari, S. L., Blackburn, M. J., Serzan, M. T., Alaoui, A., Ahn, J., & Atkins, M. B. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7020 · Cited by 30
Jan, Y., Tan, K. T., Chen, S., Yip, T. T. C., Lu, C., & Lam, A. K.-Y. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01913-4 · Cited by 29
Zhang, C., Stampfl‐Mattersberger, M., Ruckser, R., & Sebesta, C. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00975-6 · Cited by 29
Nasca, V., Barretta, F., Corti, F., Lonardi, S., Niger, M., Élez, E., Fakih, M., Jayachandran, P., Shah, A. T., Salati, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005493 · Cited by 29
Gerwert, K. B., Schörner, S., Großerueschkamp, F., Kraeft, A., Schuhmacher, D., Sternemann, C., Feder, I. S., Wisser, S., Lugnier, C., Arnold, D., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.026 · Cited by 29
Yi, J., Xue, J., Yang, L., Xia, L., & He, W. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1094189 · Cited by 29
Alouani, E. L., Mercier, M., Flecchia, C., Auclin, É., Hollebecque, A., Mazard, T., Turpin, A., Pernot, S., Cohen, R., Dutherage, M., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101574 · Cited by 29
Yoshimoto, S., Chester, N., Xiong, A., Radaelli, E., Wang, H., Brillantes, M., Gulendran, G., Glassman, P. M., Siegel, D. L., & Mason, N. J. (2023) · mAbs · doi:10.1080/19420862.2023.2287250 · Cited by 29
de la Fouchardière, C., Cammarota, A., Svrcek, M., Alsina, M., Fleitas, T., Obermannova, R. L., Wagner, D., Ting, D. Y. W., Enéa, D., Petrillo, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102890 · Cited by 28
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 28
Recent advances in gastrointestinal cancers
Bordry, N., Astaras, C., Ongaro, M., Goossens, N., Frossard, J., & Koessler, T. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i28.4493 · Cited by 29
SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis
Tong, K., Kothari, O. A., Haro, K. S., Panda, A., Bandari, M., Carrick, J. N., Hur, J., Zhang, L., Chan, C. S., Xing, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01997-x · Cited by 28
Melhem, M. R., Hanze, E., Lu, S. M., Alskär, O., Visser, S. A. G., & Gandhi, Y. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15339 · Cited by 28
Román, M. S., Torres-Jiménez, J., Pozas, J., Esteban-Villarrubia, J., Albarrán, V., Ballesteros, P. Á., Chamorro-Pérez, J., Rodriguez, D. I. R., Orejana, I., Martínez-Delfrade, Í., et al. (2023) · Cancers · doi:10.3390/cancers15030863 · Cited by 29
Voutsadakis, I. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103987 · Cited by 31
Meybodi, S. M., Far, B. F., Pourmolaei, A., Baradarbarjastehbaf, F., Safaei, M., Mohammadkhani, N., & Samadani, A. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02114-6 · Cited by 28
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers
Ros, J., Rodríguez-Castells, M., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2236794 · Cited by 29
Cutting-Edge AI Technologies Meet Precision Medicine to Improve Cancer Care
Lin, P., Tsai, Y.-S., Yeh, Y., & Shen, M.-R. (2022) · Biomolecules · doi:10.3390/biom12081133 · Cited by 27
Xu, Y., Liu, K., Li, M., Li, M., Zhou, X., Sun, M., Zhang, L., Wang, S., Liu, F., & Xu, Y. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105142 · Cited by 27
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Taïeb, J., Sullo, F. G., Lecanu, A., Bourreau, C., Barbier, E., Gandini, A., Bez, J., Mulot, C., Fiore, F. D., El-Hajbi, F., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1646 · Cited by 30
Self-citationWang, J., Xiu, J., Baca, Y., Arai, H., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Shields, A. F., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.203 · Cited by 27
Makita, K., Hamamoto, Y., Kanzaki, H., Kataoka, M., Yamamoto, S., Nagasaki, K., Ishikawa, H., Takata, N., Tsuruoka, S., Uwatsu, K., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01940-0 · Cited by 27
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Pietrantonio, F., Avallone, A., Maiello, E., Cremolini, C., Troiani, T., Martinelli, E., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.01.005 · Cited by 27
Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review
Juat, D. J., Hachey, S. J., Billimek, J., Rosario, M. P. D., Nelson, E. L., Hughes, C. C. W., & Zell, J. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab038 · Cited by 27
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 27
Wang, R., Lian, J., Wang, X., Pang, X., Xu, B., Tang, S., Shao, J., & Lu, H. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.8286 · Cited by 27
Baretti, M., Murphy, A. G., ZAHURAK, M. L., Gianino, N., Parkinson, R. M., Walker, R., Lopez-Vidal, T. Y., Zheng, L., Rosner, G. L., Ahuja, N., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01485-x · Cited by 28
Monahan, K. J., Ryan, N. A. J., Monje‐Garcia, L., Armstrong, R., Church, D. N., Cook, J. A., El‐Ghobashy, A., Lalloo, F. I., Lane, S., McDermott, F. D., et al. (2023) · BMJ Oncology · doi:10.1136/bmjonc-2023-000124 · Cited by 27
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer
Fox, D. A., Bhamidipati, D., Konishi, T., Kaur, H., You, Y. N., Raghav, K. P. S., Ge, P. S., Messick, C. A., Johnson, B., Morris, V. K., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113356 · Cited by 26
Current status and prospect of immunotherapy for colorectal cancer
Yang, W., Zheng, H., Lv, W., & Zhu, Y. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04553-z · Cited by 28
PD ‐1: A critical player and target for immune normalization
Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 27
The TGF-β superfamily as potential therapeutic targets in pancreatic cancer
Tindall, R. R., Bailey, J. M., Cao, Y., & Ko, T. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362247 · Cited by 26
Updates on the Management of Colorectal Cancer in Older Adults
O'Donnell, C., Hubbard, J. M., & Jin, Z. (2024) · Cancers · doi:10.3390/cancers16101820 · Cited by 28
Zhu, C., Lai, Y., Liu, C., Teng, L., Zhu, Y., Lin, X., Fu, X., Lai, Q., Liu, S., Zhou, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1387243 · Cited by 27
Gallois, C., Bergen, E. S., Auclin, É., Pernot, S., Higué, J., Trouilloud, I., Touchefeu, Y., Turpin, A., Mazard, T., Bianchi, A. S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103696 · Cited by 26
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan, H. T., Emilescu, R. A., Iaciu, C. I., Orlov-Slavu, C. M., Olaru, M., Popa, A. M., Jinga, M., Niţipir, C., Schreiner, O. D., & Ciobanu, R. C. (2024) · Cancers · doi:10.3390/cancers16233928 · Cited by 27
Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy
Landre, T., & Guetz, G. D. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03980-x · Cited by 26
Medical management of pancreatic cancer: from personalization to broadening treatment strategies
Dusetti, N., Bachet, J., Chanez, B., Neuzillet, C., de Mestier, L., Williet, N., Frauhoffer, N., Nicolle, R., Boilève, A., Turpin, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102973 · Cited by 28
He, J. N., Gao, Y., Sun, Z., & Liu, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529403 · Cited by 26
Li, H., Qin, J., Li, Z., Ouyang, R., Chen, Z., Huang, S., Qin, S., & Huang, Q. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01848-z · Cited by 28
Toor, S. M., Nair, V. S., Murshed, K., Nada, M. A., & Elkord, E. (2021) · Vaccines · doi:10.3390/vaccines9010064 · Cited by 27
Tissue-Agnostic Drug Development: A New Path to Drug Approval
Thein, K. Z., Lemery, S. J., & Kummar, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0554 · Cited by 26
Yu, W., Tao, Q., Zhang, Y., Yi, F., & Feng, L. (2021) · Journal of Oncology · doi:10.1155/2021/9959946 · Cited by 26
Organ Specificity and Heterogeneity of Cancer-Associated Fibroblasts in Colorectal Cancer
Miyashita, N., & Saito, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010973 · Cited by 27
Hyung, J., Cho, E. J., Kim, J., Kim, J. H., Kim, J. E., Hong, Y. S., Kim, T. W., Sung, C. O., & Kim, S. Y. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1133 · Cited by 26
Self-citationPérez-Martelo, M., González-García, A., Vidal-Ínsua, Y., Blanco-Freire, C., Brozos-Vázquez, E., Abdulkader, I., Álvarez-Fernández, J., Lázare‐Iglesias, H., García-Martínez, C., Betancor, Y. Z., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10884-8 · Cited by 26
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Díaz-Pérez, D., Mateos-Domínguez, M., & Jara, P. G. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.10.018 · Cited by 26
Emerging evidence of immunotherapy for colorectal cancer
Miyamoto, Y., Ogawa, K., Ohuchi, M., Tokunaga, R., & Baba, H. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12633 · Cited by 27
Li, C. M. Y., Tomita, Y., Dhakal, B., Li, R., Li, J., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., & Fenix, K. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006764 · Cited by 26
Deng, X., Yang, J., Zhang, Y., Chen, X., Wang, C., Suo, H., & Song, J. (2023) · Foods · doi:10.3390/foods12193706 · Cited by 28
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
Noori, M., Jafari‐Raddani, F., Davoodi‐Moghaddam, Z., Delshad, M., Safiri, S., & Bashash, D. (2024) · Cancer Cell International · doi:10.1186/s12935-023-03183-3 · Cited by 26
Cui, Y., Zhang, P., Liang, X., Xu, J., Liu, X., Wu, Y., Zhang, J., Wang, W. T., Zhang, F., & Guo, R. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3991639 · Cited by 26
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 26
Fumet, J.-D., Latour, C., Nuttin, L., Dérangère, V., Ilie, A., Russo, P., Hampe, L., Daumoine, S., Thibaudin, M., Truntzer, C., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0079 · Cited by 25
Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer
Dmello, R. S., To, S. Q., & Chand, A. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042067 · Cited by 25
Salewski, I., Henne, J., Engster, L., Schneider, B., Lemcke, H., Skorska, A., Berlin, P., Henze, L., Junghanß, C., & Maletzki, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115990 · Cited by 25
Pietrantonio, F., Lonardi, S., Corti, F., Infante, G., Élez, E., Fakih, M., Jayachandran, P., Shah, A. T., Salati, M., Fenocchio, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003370 · Cited by 25
Fountzilas, C. K., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1650 · Cited by 25
Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer
Ostios-García, L., Villamayor, J., Garcia-Lorenzo, E., Viñal, D., & Feliú, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i40.6775 · Cited by 25
Du, F., & Liu, Y. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24141 · Cited by 26
Emerging actionable targets to treat therapy-resistant colorectal cancers
Grassilli, E., & Cerrito, M. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.96 · Cited by 26
Lefler, D. S., Snook, A. E., & Bashir, B. (2022) · Immunotherapy · doi:10.2217/imt-2022-0012 · Cited by 25
ICIs-Related Cardiotoxicity in Different Types of Cancer
Dong, M., Yu, T., Zhang, Z., Zhang, J., Wang, R., Tse, G., Liu, T., & Zhong, L. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070203 · Cited by 25
Zhang, Z., Xie, T., Qi, C., Zhang, X., Shen, L., & Peng, Z. (2022) · Cancers · doi:10.3390/cancers14153736 · Cited by 25
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 26
Chung, B.-S., Liao, I., Lin, P., Wu, S., Kang, J., Lin, B., Chen, P.-C., Chan, R., Lee, C., Shen, M.-R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113277 · Cited by 25
Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era
Shimozaki, K., Nakayama, I., Hirota, T., & Yamaguchi, K. (2023) · Cells · doi:10.3390/cells12071049 · Cited by 25
Grypari, I. M., Tzelepi, V., & Gyftopoulos, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411418 · Cited by 26
Williams, C. J. M., Gray, R. G., Hills, R. K., Shires, M., Zhang, L., Zhao, Z., Gardner, T., Sapanara, N. L., Xu, X., Bai, I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02030 · Cited by 25
Zhang, R., Wang, Y., Liu, D., Luo, Q., Du, P., Zhang, H., & Wu, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870848 · Cited by 25
Li, C. M. Y., Li, R., Drew, P. A., Price, T. J., Smith, E., Maddern, G. J., Tomita, Y., & Fenix, K. A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102665 · Cited by 25
Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
de Torres, C. S., Baraibar, I., Gonzalez, N. S., Ros, J., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136967 · Cited by 26
CSCO guidelines for colorectal cancer version 2024: Updates and discussions
Chen, L., Hu, H., Yuan, Y., & Weng, S. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.03.01 · Cited by 25
Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
Liu, M., Liu, Q., Hu, K., Dong, Y., Sun, X., Zou, Z., Ji, D., Liu, T., & Yu, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104497 · Cited by 24
Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients
Margalit, O., Stemmer, A., Chapin, W. J., Shacham‐Shmueli, E., Kopetz, S., André, T., Overman, M. J., Pietrantonio, F., & Boursi, B. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114336 · Cited by 24
Self-citationYamaguchi, T., Tsuchihashi, K., Ueno, S., Uehara, K., Taguchi, R., Ito, M., Isobe, T., Imajima, T., Kitazono, T., Tanoue, K., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104108 · Cited by 25
Jasmine, F., Haq, Z., Kamal, M., Raza, M., Silva, G. D., Gorospe, K., Paul, R., Strzempek, P., Ahsan, H., & Kibriya, M. G. (2021) · Cancers · doi:10.3390/cancers13194956 · Cited by 24
Molecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 26
Rossini, D., Germani, M. M., Lonardi, S., Pietrantonio, F., Dell’Aquila, E., Borelli, B., Allegrini, G., Maddalena, G., Randon, G., Marmorino, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.019 · Cited by 25
MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer
Wu, Q., Yue, X., Liu, H., Zhu, Y., Ke, H., Yang, X., Yin, S., Li, Z., Zhang, Y., Hu, T., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.001 · Cited by 24
Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response
Zeng, Z., Gu, S. S., Wong, C. J., Yang, L., Ouardaoui, N., Li, D., Zhang, W., Brown, M. A., & Liu, X. S. (2022) · Science Advances · doi:10.1126/sciadv.abm8564 · Cited by 25
Cohen, I., Pareja, F. G., Socci, N. D., Shen, R., Doane, A. S., Schwartz, J., Khanin, R., Morris, E. A., Sutton, E. J., & Blasberg, R. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880959 · Cited by 24
Yang, L., Chen, X., Lee, C., Shi, J., Lawrence, E. B., Zhang, L., Li, Y., Gao, N., Jung, S. Y., Creighton, C. J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02689-y · Cited by 24
Metadata
- Authors
- André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., de la Fouchardiere, C., Rivera, F., Elez, E., Bendell, J., Le, D. T., Yoshino, T., Van Cutsem, E., Yang, P., Farooqui, M. Z. H., Marinello, P., & Diaz, L. A.
- Affiliations
- University College Hospital (GB)
- From Sorbonne Université and Hôpital Saint Antoine, Paris (T.A.), Bordeaux University Hospital, Bordeaux (D.S.), and Léon Bérard Center, Lyon (C.F.) — all in France; University College Hospital, NHS Foundation Trust, London (K.-K.S.); Asan Medical Center, University of Ulsan, Seoul, South Korea (T.W.K.); Herlev and Gentofte Hospital, Herlev (B.V.J.), and University Hospital of Southern Denmark, Vejle (L.H.J.) — both in Denmark; Amsterdam University Medical Center, University of Amsterdam, Amsterdam ...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-03
- Volume
- 383
- Issue
- 23
- Pages
- 2207-2218
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3110528877
- Cited by
- 3,099
- References
- 27
- Citations by year
- 2026: 522 · 2025: 536 · 2024: 526 · 2023: 587 · 2022: 554 · 2021: 367 · 2020: 4
- FWCI
- 136.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
- Lirias (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- pembrolizumab, microsatellite instability-high, mismatch repair deficiency, advanced colorectal cancer, metastatic colorectal cancer, anti-PD-1 therapy, immunotherapy, first-line therapy, 5-fluorouracil chemotherapy, bevacizumab, cetuximab, progression-free survival, overall survival, treatment-related adverse events, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplastic Syndromes, Hereditary, Biomarkers, Tumor, Colorectal Neoplasms, Kaplan-Meier Estimate, Microsatellite Instability, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
